SI
FDMT icon

Sofinnova Investments’s 4D Molecular Therapeutics FDMT Stock Holding History

Sofinnova Investments’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-271,155
Closed -$5.69M – 73
2024
Q2 		$5.69M Buy
271,155
+72,969
+37% +$1.83M 0.3% 55
2024
Q1 		$6.31M Buy
+198,186
New +$5.06M 0.35% 47

Other funds holding FDMT

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sofinnova Investments's FDMT Position: Q3 2024 in Review

Sofinnova Investments sold out of 4D Molecular Therapeutics (FDMT) in Q3 2024, closing a stake of 271,155 shares — an estimated $5.69M sold.

Sofinnova Investments first reported a position in FDMT in Q1 2024 and held it in 2 quarters. The position peaked at $6.31M in Q1 2024. 140 funds tracked by Wall St. Rank hold FDMT as of Q3 2024.

  • Sofinnova Investments reported no remaining 4D Molecular Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Sofinnova Investments sold 271,155 4D Molecular Therapeutics shares in Q3 2024, an estimated $5.69M.
  • Sofinnova Investments first reported a position in 4D Molecular Therapeutics in Q1 2024 and held it in 2 quarters.
  • Sofinnova Investments's 4D Molecular Therapeutics position peaked at $6.31M in Q1 2024.
  • 140 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q3 2024.

Based on Sofinnova Investments's 13F filing for Q3 2024, filed 13 Nov 2024.